Philadelphia chromosome

(redirected from Bcr-abl)
Also found in: Medical.

Philadelphia chromosome

[¦fil·ə¦del·fyə ′krō·mə‚skōp]
(pathology)
An abnormally small G-group chromosome found in the hematopoietic cells of most patients with chronic granulocytic leukemia.
References in periodicals archive ?
The company said this makes Tasigna the first and only BCR-ABL tyrosine kinase inhibitor (TKI) to include data about attempting treatment discontinuation in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP) after achieving sustained deep molecular response of MR4.
The researchers also used their technique to analyze mutations in Bcr-Abl that enable it to become resistant to the drug imatinib, known as Gleevec.
First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
This changed chromosome 22 with BCR-ABL fusion gene is called Ph' chromosome.
La caracterizacion de la anomalia molecular del cromosoma Filadelfia en la LMC, la traslocacion BCR-ABL fue hecha por Janet Rowley en 1973, y progresivamente se logro establecer que la fusion de ABL cuya actividad en estado natural implica regulacion de la proliferacion, adherencia y apoptosis se descontrola al fusionarse con el BCR (6).
The primary target for Iclusig is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
The primary target of Iclusig kinase inhibitor is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).
BCR-ABL expression was quantitated using real-time quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) according to Europe Against Cancer Protocol [19] using ABL as control gene.
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.
The very high (arguably, complete) association of the BCR-ABL fusion with this disease led to early efforts at standardizing a molecular method of MRD quantification.
Cells that contain BCR-ABL are the equivalent of a car with the accelerator stuck on full.